Anthropic recently announced that it intends to engage directly in drug development, not to become the next pharmaceutical giant, but because the company believes it cannot build AI capable of accelerating science without actually doing science.
For years, the working assumption across the life sciences sector has been that pharmaceutical companies do the science, and AI companies provide the tools. The relationship has been that of vendor and customer, each staying in its lane. Anthropic's announcement challenges that assumption directly.
What Anthropic is actually pursuing is firsthand experience deploying AI agents to solve real scientific problems in the real world. The logic mirrors software development: you cannot build the world's best software developer without writing software. By that same reasoning, building the world's best scientific AI likely requires doing science. Anthropic is betting on it. By working directly on drug development, Anthropic will generate the training data, edge cases, failure modes, and domain-specific knowledge that no pharmaceutical client relationship could fully provide. The result, over time, is an AI company that understands the science, not just the workflow.
A Shifting Competitive Landscape
The pharmaceutical industry currently buys AI tools. Within a decade, AI companies may possess the most advanced scientific reasoning models, the largest biological knowledge bases, and the most sophisticated multi-agent research systems, while simultaneously generating discoveries of their own. That shifts the relationship from a straightforward vendor arrangement to something more complicated: AI companies as partners, yes, but also as potential competitors with proprietary scientific capabilities and growing research portfolios.
Agentic AI further complicates the picture. Small biotech firms may soon be able to deploy large networks of AI research agents, effectively narrowing the resource gap that has historically favored large pharmaceutical organizations. The competitive advantage of scale becomes less certain when AI can amplify the output of a smaller team.
The Regulatory Questions Nobody Has Answered
If AI systems become active participants in scientific discovery rather than passive tools, the regulatory and legal frameworks governing drug development will need to catch up quickly. Several questions remain unresolved: Who holds intellectual property rights when an AI agent generates a novel compound or hypothesis and
How should regulators validate discoveries that originate from AI-driven processes? Perhaps more importantly: Who bears accountability when an AI system produces flawed science that reaches a clinical setting? The phrase "human in the loop" has been widely cited as a safeguard, but in practice it often describes accountability more than active oversight. Regulators at the FDA and other agencies will need to draw clearer lines before AI-generated drug discoveries move routinely through clinical pipelines.
Where This Is Heading
The trajectory is difficult to ignore. Within five years, major pharmaceutical companies will likely operate large fleets of specialized AI research agents as standard practice. Within ten years, some AI companies may hold drug portfolios, patents, and clinical-stage assets that make them functionally indistinguishable from biopharma firms.
The more important question for life sciences organizations to ask is not how to use AI to develop drugs. The more useful question is whether competitive drug development will remain viable without deep AI integration across research, clinical, and regulatory functions. Anthropic's announcement suggests that window may be narrowing faster than most of the industry has anticipated.
InfoPathways works with life sciences organizations navigating the shift from AI as a productivity tool to AI as an active participant in research and regulated workflows. If your organization is evaluating how agentic AI fits into your operations, compliance obligations, or competitive strategy, reach out to InfoPathways to start that conversation.
